Gene Therapy

Showing 1718 articles
Business

IHS Towers: A Deep-Value Play Emerges as Currency Headwinds Shift

IHS Holding Limited, a leading telecom tower operator in emerging markets, is seeing a dramatic reversal in its investment narrative. Long pressured by currency devaluations, the company now stands to benefit from FX tailwinds, operational improvements, and surging data demand, presenting a compelling bull case at a valuation far below peers.

Business

C4 Therapeutics: Can Its Protein-Degrading Tech Ignite a Biotech Rally?

Amid a challenging market for biotech, C4 Therapeutics (NASDAQ: CCCC) is drawing investor attention with its targeted protein degradation platform. Backed by industry giants and focused on niche cancers, the clinical-stage company presents a high-risk, high-reward proposition. We examine the bull case and the road ahead.

Business

Credo Technology: The Quiet Backbone Powering the AI Boom

As AI infrastructure scales, reliability becomes paramount. Credo Technology Group, once a niche connectivity player, is now seeing explosive growth as its solutions become critical to preventing costly failures in hyperscale data centers. With revenue soaring over 270% and margins expanding, the debate is whether Credo is a cyclical beneficiary or the foundational 'toll road' of modern AI computing.

Business

AerCap Holdings: The Aviation Giant Flying Under the Radar

AerCap Holdings N.V., the world's largest aircraft lessor, is drawing renewed attention from value investors. Despite geopolitical headwinds and a cyclical reputation, its robust cash flows, industry dominance, and compelling valuation present a strong case for a rerating, as global travel demand outpaces constrained aircraft supply.

Business

Palomar Holdings: The Specialty Insurer Defying Market Expectations

Amid a volatile market, specialty insurer Palomar Holdings (PLMR) presents a compelling growth story. With a disciplined underwriting strategy, robust risk management, and a track record of doubling profits every few years, the company trades at multiples that may significantly undervalue its consistent execution and expansion potential.